Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fractyl Health Inc (GUTS)

Fractyl Health Inc (GUTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,347
  • Shares Outstanding, K 137,044
  • Annual Sales, $ 90 K
  • Annual Income, $ -68,690 K
  • EBIT $ -99 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.96
  • Price/Sales 2,829.30
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.22
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +63.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +89.66%
on 11/07/25
2.0500 -1.93%
on 12/04/25
+0.8804 (+77.91%)
since 11/05/25
3-Month
0.9100 +120.92%
on 09/08/25
2.0500 -1.93%
on 12/04/25
+1.0876 (+117.86%)
since 09/05/25
52-Week
0.8250 +143.68%
on 08/06/25
3.0300 -33.65%
on 06/09/25
-0.1296 (-6.06%)
since 12/05/24

Most Recent Stories

More News
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with...

GUTS : 2.0104 (+1.54%)
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root...

GUTS : 2.0104 (+1.54%)
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-label...

GUTS : 2.0104 (+1.54%)
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes...

GUTS : 2.0104 (+1.54%)
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the...

GUTS : 2.0104 (+1.54%)
Fractyl Health Approves Share Issuance in Special Meeting

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

GUTS : 2.0104 (+1.54%)
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”...

GUTS : 2.0104 (+1.54%)
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain...

GUTS : 2.0104 (+1.54%)
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

BURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat...

GUTS : 2.0104 (+1.54%)
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation;...

GUTS : 2.0104 (+1.54%)

Business Summary

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Fractyl Health is based in Lexington, MA.

See More

Key Turning Points

3rd Resistance Point 2.2567
2nd Resistance Point 2.1533
1st Resistance Point 2.0667
Last Price 2.0104
1st Support Level 1.8767
2nd Support Level 1.7733
3rd Support Level 1.6867

See More

52-Week High 3.0300
Fibonacci 61.8% 2.1877
Last Price 2.0104
Fibonacci 50% 1.9275
Fibonacci 38.2% 1.6673
52-Week Low 0.8250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar